Cochleates made with soy phosphatidylserine
Unpurified or low pure soy phosphatidylserine is used to make cochleates. The cochleates contain about 40-74% soy phosphatidylserine, a multivalent cation and a biological active. A preferred cochleate contains the antifungal agent amphotericin B.
1. A cochleate comprising:
a soy-based phospholipid comprising about 45% to 55% by weight soy phosphatidylserine,
a multivalent cation, and
a bioactive drug,
wherein the soy phosphatidylserine used to make the cochleate is associated with less than 3 ppm calcium.
2. The cochleate of claim 1 , wherein the soy-based phospholipid is a mixture composed of at least soy phosphatidylserine and phosphatidic acid.
3. The cochleate of claim 1 , wherein the bioactive drug is at least one member selected from the group consisting of a protein, a small peptide, a polynucleotide, an aminoglycoside, an antiviral agent, an anesthetic, an antibiotic, an antifungal agent, an anticancer agent, an immunosuppressant, a steroidal anti-inflammatory agent, a non-steroidal anti-inflammatory agent, a tranquilizer, a nutritional supplement, an herbal product, a vitamin and a vasodilatory agent.
4. The cochleate of claim 3 wherein the bioactive drug is at least one member selected from the group consisting of an aminoglycoside, amphotericin B, acyclovir, adriamycin, cabamazepine, curcumin, melphalan, nifedipine, indomethacin, naproxen, estrogens, testosterones, steroids, phenytoin, ergotamines, cannabinoids, rapamycin, propanidid, propofol, alphadione, echinomycine, miconazole nitrate, teniposide, a taxane, paclitaxel, and taxotere.
5. The cochleate of claim 1 , wherein the multivalent cation is Ca++, Zn++, Ba++, or Mg++.
6. The cochleate of claim 1 , wherein the multivalent cation is Ca++.
7. The cochleate of claim 1 , wherein the bioactive drug is amphotericin B.
8. The cochleate of claim 1 , wherein the bioactive drug is curcumin.
9. The cochleate of claim 1 , wherein the bioactive drug is an aminoglycoside or amikacin.
10. The cochleate of claim 1 , wherein the cochleate further comprises bile salts.
11. The cochleate of claim 10 , wherein the weight ratio of soy-based phospholipid to the bile salts is between 20:1 and 0.5:1.
12. A method of treating a patient with a fungal infection, the method comprising administering to the patient an effective anti-fungal amount of a cochleate which comprises (i) a soy-based phospholipid that comprises about 45% to 55% by weight soy phosphatidylserine, (ii) a multivalent cation and (iii) an anti-fungal agent,
wherein the soy phosphatidylserine used to make the cochleate is associated with less than 3 ppm calcium.
13. The method of claim 12 , wherein the antifungal agent is amphotericin B.
14. A method of treating a patient with a bacterial infection, the method comprising administering to the patient an effective anti-bacterial amount of a cochleate which comprises (i) a soy-based phospholipid that comprises about 45% to 55% by weight soy phosphatidylserine, (ii) a multivalent cation and (iii) an antibiotic agent,
wherein the soy phosphatidylserine used to make the cochleate is associated with less than 3 ppm calcium.
15. The method of claim 14 , wherein the antibiotic agent is an aminoglycoside.
16. The method of claim 14 , wherein the antibiotic agent is amikacin.
17. The method of claim 12 , wherein the multivalent cation is Ca++, Zn++, Ba++, or Mg++.
18. The method of claim 12 , wherein the multivalent cation is Ca++.
19. The method of claim 14 , wherein the multivalent cation is Ca++, Zn++, Ba++, or Mg++.
20. The method of claim 14 , wherein the multivalent cation is Ca++.